Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389675 · ClinicalTrials.gov registry record · Phase 3
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 661
- Enrollment target
NCT00389675 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 661 participants.
The verdict
NCT00389675, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 661 participants
- Enrollment target
Study Summary
This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan (optimized dose) as compared to an active control, administered orally.
Interventions
- DRUG Guanfacine
- DRUG Darusentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389675
The ClinicalTrials.gov registry entry for NCT00389675 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guanfacine is the first listed.
NCT00389675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389675 about?
NCT00389675 is a clinical study titled "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension". This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the lo...
What is the current status of trial NCT00389675?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 661 participants. The study started on 2007-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00389675?
The interventions under investigation include: Guanfacine (DRUG), Darusentan (DRUG).
Who is sponsoring clinical trial NCT00389675?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.